Biohaven Pharmaceuticals announced positive results from an early-stage study of a new drug, BHV-1300, which reduces levels of the disease-causing immune molecule IgG implicated in autoimmune disorders. The drug showed a reduction in IgG levels by 5% to 37% in healthy volunteers without adverse effects on liver enzymes. This new antibody medicine works by transporting harmful proteins to the liver for removal from the body. While the results were deemed positive as a proof of concept, they fell short of investor expectations. The drug has potential applications in treating conditions like rheumatoid arthritis and myasthenia gravis.
Source link
Biohaven protein-degrader drug falls short of investor expectations in early test
